L-Ascorbic Acid Tocopherol Phosphate Salt Oral Composition for MMP Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a lack of evidence on the effect of L-ascorbic acid dl-α-tocopherol phosphoric acid diester in the oral region, particularly in preventing or suppressing periodontal disease, oral mucositis, and caries.
Innovation Solution
A composition containing L-ascorbic acid dl-α-tocopherol phosphoric acid diester alkali metal salt, specifically the potassium salt, is formulated to enhance oral mucosal epithelial barrier function and inhibit matrix metalloproteinase activity, thereby preventing periodontal disease and oral mucositis, and inhibiting caries progression.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If L-ascorbic acid dl-α-tocopherol phosphoric acid diester is used in oral compositions, then oral mucosal epithelial barrier function is enhanced and MMP activity is inhibited, but the composition may interact adversely with other oral care ingredients
Solution Approach 1:
The patent identifies polyoxyethylene alkyl phenyl ethers, polyoxyethylene alkyl ethers, and polyoxyethylene fatty acid esters as ingredients that may adversely interact with EPC. The specification excludes these problematic ingredients and instead recommends alternative nonionic surfactants such as sorbitan fatty acid esters, sorbitol fatty acid esters, and diethyl sebacate, which do not cause adverse interactions while maintaining the beneficial effects of EPC on oral mucosal barrier function and MMP inhibition.
2Reliability
If EPC alkali metal salt is included in oral composition, then periodontal disease and oral mucositis are prevented, but the composition complexity increases
Solution Approach 1:
The patent specifies precise concentration ranges for EPC alkali metal salt (0.001 to 1 mass%, preferably 0.01 to 0.5 mass%) and provides detailed guidelines on selecting appropriate alkali metal salts (potassium, sodium, lithium). It also outlines specific constraints on other ingredient concentrations and types, thereby optimizing the composition formulation to achieve therapeutic effects while managing formulation complexity through standardized parameter specifications.
Data Source
AI summary
Provided is an oral composition comprising an L-ascorbic acid dl-α-tocopherol phosphoric acid diester alkali metal salt. The composition according to the present disclosure is capable of suppressing disruption of the oral mucosal epithelial barrier function and/or inhibiting the activity of matrix metalloproteinases (MMPs). Thus, the composition according to the present disclosure is capable of preventing the onset of periodontal disease and/or suppressing the progression of periodontal disease.